TFC Financial Management, Inc.
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1827844
BOSTON, MA
Position in HALO
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$16,514
+$2,878 QoQ
Shares Held
211
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#559
of 664 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TFC Financial Management, Inc. holds $462,229 across 45 Biotechnology names. HALO ranks #8 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
316 | $156,966 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
89 | $55,495 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
1,650 | $51,579 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
620 | $33,814 | |
| 5 | REPL |
Replimune Group, Inc.
|
2,691 | $29,789 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
72 | $21,674 | |
| 7 | MRNA |
Moderna, Inc.
|
264 | $18,487 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
This page
|
211 | $16,514 |
All Filings in HALO
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,514 | 211 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $13,636 | 211 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $14,200 | 211 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $15,401 | 210 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $9,207 | 177 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $11,358 | 178 | Shares | Sole | 2025-04-24 | |
| 2024-12-31 | $6,549 | 137 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $5,380 | 94 | Shares | Sole | 2024-10-25 | |
| No filing history on record for this holder in this stock. | ||||||